Literature DB >> 15667542

Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients.

Margaret Kennedy1, Astrid C M Andreescu, Marc S Greenblatt, Hongyu Jiang, Christian A Thomas, Laurie Chassereau, Cheung Wong, Peter Durda, Mary Cushman.   

Abstract

Cancer patients have an increased risk of venous thrombosis (VT). The association of factor V Leiden (FVL) and the prothrombin 20210A variant with VT in cancer patients is not established. We genotyped 101 cancer patients with VT and 101 cancer patients without VT for these polymorphisms. Five cases and three controls were heterozygous for FVL, yielding an odds ratio of 1.7 (95% confidence interval (CI) 0.3-10.7). Five cases and no controls were heterozygous for prothrombin 20210A, for an odds ratio of 6.7 (95% CI 0.9-infinity). Prothrombin 20210A may be associated with VT risk among cancer patients.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15667542     DOI： 10.1111/j.1365-2141.2004.05327.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  9 in total

1.  Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism.

Authors:  Olga V Gran; Erin N Smith; Sigrid K Brækkan; Hilde Jensvoll; Terry Solomon; Kristian Hindberg; Tom Wilsgaard; Frits R Rosendaal; Kelly A Frazer; John-Bjarne Hansen
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

Review 2.  Venous thromboembolism and cancer: a systematic review.

Authors:  Celso Arrais Rodrigues; Renata Ferrarotto; Roberto Kalil Filho; Yana A S Novis; Paulo M G Hoff
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

Review 3.  Epidemiology and risk factors for venous thrombosis.

Authors:  Mary Cushman
Journal:  Semin Hematol       Date:  2007-04       Impact factor: 3.851

4.  Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.

Authors:  Aydan Eroglu; Arzu Ulu; Ragip Cam; Cengiz Kurtman; Nejat Akar
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

5.  Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

Authors:  F S Falvella; C Cremolini; R Miceli; F Nichetti; S Cheli; C Antoniotti; G Infante; A Martinetti; F Marmorino; E Sottotetti; R Berenato; M Caporale; A Colombo; F de Braud; M Di Bartolomeo; E Clementi; F Loupakis; F Pietrantonio
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

Review 6.  Assessing risk of venous thromboembolism in the patient with cancer.

Authors:  Alok A Khorana; Gregory C Connolly
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

Review 7.  Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants.

Authors:  Waqas Qureshi; Zeeshan Ali; Waseem Amjad; Zaid Alirhayim; Hina Farooq; Shayan Qadir; Fatima Khalid; Mouaz H Al-Mallah
Journal:  Front Cardiovasc Med       Date:  2016-07-28

8.  Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.

Authors:  Andrés J Muñoz Martín; Israel Ortega; Carme Font; Vanesa Pachón; Victoria Castellón; Virginia Martínez-Marín; Mercedes Salgado; Eva Martínez; Julia Calzas; Ana Rupérez; Juan C Souto; Miguel Martín; Eduardo Salas; Jose M Soria
Journal:  Br J Cancer       Date:  2018-03-28       Impact factor: 7.640

9.  Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study.

Authors:  Adeline Heraudeau; Aurélien Delluc; Mickaël Le Henaff; Karine Lacut; Christophe Leroyer; Benoit Desrues; Francis Couturaud; Cécile Tromeur
Journal:  PLoS One       Date:  2018-05-18       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.